Navigation Links
FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery
Date:2/1/2012

s to recommend consideration of at least three years of adjuvant therapy with Gleevec for patients with high-risk GIST(2).

In addition to extending the Gleevec label to three-year treatment duration in patients with KIT+ GIST after surgery, the FDA has agreed that all accelerated post-approval commitments for this indication have been met, confirming the clinical benefit of adjuvant treatment with Gleevec.

Study details
The SSG XVIII clinical trial was conducted by the Scandinavian Sarcoma Group (SSG) and the Sarcoma Group of the Arbeitsgemeinschaft Internistische Onkologie (AIO). This trial was a multicenter, prospective, randomized study for the evaluation of adjuvant treatment with Gleevec of histologically confirmed KIT+ GIST(5).

The primary endpoint of the study was to compare, within the first five years, recurrence-free survival in patients with a greater than 50% estimated risk of GIST disease recurrence, following diagnosis and treatment with adjuvant Gleevec for either 12 or 36 months. The secondary endpoints included overall survival and treatment safety(1).

Three hundred ninety-seven patients entered the study. Inclusion criteria for risk of recurrence was defined as tumor diameter >5.0 cm and mitotic count >5/50 high power fields (HPFs); or tumor diameter >10.0 cm, any mitotic count; or tumor of any size with a mitotic count >10/50 HPFs; or tumors ruptured into the peritoneal cavity.

Recurrence-free survival was longer in the 36-month group compared to the 12-month group (HR 0.46, 95% CI 0.32-0.65; p<0.0001). Patients assigned to 36 months of Gleevec after surgery had longer overall survival (HR 0.45, 95% CI 0.22-0.89; p=0.0187). Almost all patients experienced side effects while taking Gleevec. Gleevec was generally well tolerated. The proportion of patients who discontinued Gleevec during the assigned treatment period for reasons other than GIST recurrence was 26% over the full three yea
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... BOTHELL, Wash. and VANCOUVER ... OGXI ) announced today that it will report ... 13, 2015. Company management will host a conference call ... provide an overview of financial results, clinical development programs ... access the webcast, log on to the Investor Relations ...
(Date:7/30/2015)... July 30, 2015 PTC Therapeutics, Inc. (NASDAQ: ... reported financial results for the second quarter ending June ... many fronts across the organization.  We are excited to ... dystrophy clinical trial ever conducted with topline results expected ... Chief Executive Officer, PTC Therapeutics, Inc. "Translarna is now ...
(Date:7/30/2015)... , July 30, 2015 Tianyin Pharmaceutical ... pharmaceutical company that specializes in the patented biopharmaceutical, modernized ... ingredients (API), provided updates regarding the notice it received ... (the "Exchange") indicating that the Company was below certain ... in Sections 134 and 1101 of the NYSE MKT ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
... NEW YORK, March 15, 2012 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p0578259/Vaccines---Asia.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This market ... on the actual market situation, trends and ...
... that closes a hole in patients, hearts is no more ... a new study published in the March 15 issue of ... the CLOSURE I trial, clinical researchers compared a catheter procedure ... or transient ischemic attacks (TIAs) in patients between 18 and ...
Cached Medicine Technology:Vaccines - Asia 2Landmark Study Finds Expensive Catheter Procedure to Close Hole in Heart No More Effective Than Medical Therapy to Prevent Strokes 2Landmark Study Finds Expensive Catheter Procedure to Close Hole in Heart No More Effective Than Medical Therapy to Prevent Strokes 3
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Ticket Down is a reputable source of ... Women's National Soccer Team will face the Australia Women's National Team in conjunction with their ... score of 5-2. Carli Lloyd from the USA team was awarded the Golden Ball ...
(Date:7/31/2015)... Miami, FL (PRWEB) , ... July 31, 2015 , ... ... die everyday as a direct result of heroin use and eventual overdoses. Thricefold deaths ... is struggling to get a handle on the Sarasota heroin epidemic, which was spurred ...
(Date:7/31/2015)... ... , ... Physical therapy for knee osteoarthritis is an important part of ... the patient from doing what they want or need to do. The patient may have ... stairs. The patient's exercise regime may be limited by the pain in their knee. When ...
(Date:7/31/2015)... Grand Rapids, MI (PRWEB) , ... July 31, ... ... Living Pure Essential Oils are 100% organic, natural, therapeutic-grade oils from ingredients sourced ... founder, Ashley Eilers, explains that “With considerable effort, we have developed the highest-quality ...
(Date:7/31/2015)... ... 31, 2015 , ... “ Crack’em ” was featured on NewsWatch as part ... to consumers. Amanda Forstrom, a technology expert and special reporter for NewsWatch, conducted the ... cooking. , Cooking can be a very messy experience, especially when cracking eggs. Cracking ...
Breaking Medicine News(10 mins):Health News:Cheap USA vs. Australia Tickets at Ford Field in Detroit, MI: Ticket Down Slashes Ticket Prices for Australia vs. USWNT International Friendly Match at Ford Field 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 3Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 2Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 3Health News:Living Pure Essential Oils takes Therepeutic Essential Oil Market by Storm 2Health News:Make Less Mess while Cooking with Crack’em 2
... 20, 2007 -- A Las Vegas business and Oak Ridge ... risk from dehydration or congestive heart failure. , The task ... was to improve and miniaturize Noninvasive Medical Technologies ZOE, a ... fluid. This is of great importance to members of the ...
... were given Nobel Direct dental implants, the risk of the ... at the Sahlgrenska Academy in Sweden shows that eight per ... was launched in 2004 by Nobel Biocare AB. The implants ... directly into the jawbone without having to first lift up ...
... Holdings Corp. (Nasdaq:,HMSY) today announced that it will present ... held January 7-10, 2008 at the Westin,St. Francis in ... Robert Holster, Chairman and CEO of HMS Holdings Corp., ... Time., A live broadcast of the Company,s presentation ...
... Funding Supports Phase 3 Program for Lead ... Cogentus Pharmaceuticals,Inc. announced today that it ... million to support the clinical development of ... http://www.newscom.com/cgi-bin/prnh/20071112/COGENTUSLOGO ), The Series C ...
... Chichester, UK, December 20, 2007 Wiley-Blackwell, the ... John Wiley & Sons, Inc (NYSE: JWa), (NYSE: ... dedicated to improving healthcare decision-making globally, today announced ... with free one-click access to all residents of ...
... LTC,Financial Partners, the nation,s most experienced long ... size since 2005, to more than 400,field underwriters ... what,s,happening in the long term care insurance field, ... *(Photo Caption: LTC Financial CEO Cameron Truesdell.), ...
Cached Medicine News:Health News:Nevada company, ORNL develop potential lifesaver 2Health News:Gloomy forecast for Nobel Direct after 3 years 2Health News:Cogentus Pharmaceuticals Completes $62.5 Million Private Financing 2Health News:Low-income countries now have free, one-click access to Cochrane Library 2Health News:The Long Term Care Insurance Explosion; January Conference to Celebrate Rapid Growth of LTC Protection and Light Fuse of Further Expansion 2
The Leica M500 OH3 is an advanced surgical microscope used by neurosurgeons. It is a smart system combining the best optical performance available on the market with an innovative and unique stand....
Surgical Loupes...
... MAGNETOM Allegra is the ultimate brain ... been optimized for best image quality ... all in a highly compact design. ... diagnosing stroke, epilepsy, tumor and multiple ...
Signa Profile is built on the Signa foundation to deliver speed & image quality....
Medicine Products: